( BETHESDA Md.--(BUSINESS WIRE)--May 7 ...)Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting,Health

BETHESDA, Md.--(BUSINESS WIRE)--May 7, 2007 - REGENERX BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com - Dr. Gabriel Sosne will be speaking at the 2007 Association for Research in Vision and Ophthalmology (ARVO) meeting in Ft. Lauderdale, Florida on May 9th to discuss TB4's ability to inhibit corneal neutrophil infiltration. Neutrophil infiltration is a process closely associated with inflammation that, if not properly controlled, can cause substantial tissue and organ damage. According to Dr. Sosne, TB4 inhibits neutrophil infiltration by decreasing and/or suppressing the expression of several different types of inflammatory molecules, some of which have been previously identified and the subject of several ophthalmic publications.

"The importance of this finding is that it gives us a better understanding of the pathway TB4 uses to reduce inflammation and increases the clinical relevance of TB4 as we translate the work from the laboratory bench into patients. Our understanding of the neutrophil connection applies not only to TB4's mechanism of action in eye wounds, but likely also at organ and tissue sites such as the skin and heart, among others," said Dr. Sosne, Assistant Professor of Ophthalmology at Wayne State University and the Kresge Eye Institute in Detroit, Michigan.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as the cornerstone of its therapeutic platform. The technology platform has many potential applications in both the pharmaceutical and consumer products sectors. RegeneRx holds nearly 60 world-wide paten
'"/>

Page: 1 2 3
Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference